Overview

A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)

Status:
Completed

Trial end date:
2014-02-28

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, double-dummy, placebo-controlled, three-way cross-over, single centre study in participants with asthma undergoing inhalation of methacholine and adenosine triphosphate (ATP) to assess the provocative concentration (PC20) response of two dose levels of gefapixant (AF-219) compared with placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Afferent Pharmaceuticals, Inc.

Treatments:

Cisplatin
Ifosfamide
Mesna
Methacholine Chloride
Mitomycin